<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="805932c3-0a3a-4eac-a6ab-9b8cca1929bd"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title/>
   <effectiveTime value="20120612"/>
   <setId root="c9449292-e81e-486a-84e1-bb9dd0f612c5"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
            <name>Physicians Total Care, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194123980" root="1.3.6.1.4.1.519.1"/>
                        <name>Physicians Total Care, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="relabel"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="repack"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b7ec4a93-6c91-46e9-b75f-42be5254ac31"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20120612"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54868-3362" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Flurbiprofen<suffix/>
                        </name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>flurbiprofen</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0378-0093" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5GRO578KLP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FLURBIPROFEN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5GRO578KLP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FLURBIPROFEN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VH2XOU12IE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYDEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOLS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-3362-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-3362-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54868-3362-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA074358" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19970224"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BROWN">
                              <originalText>beige</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="11" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">M;93</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="id_db87b37e-c8d5-4967-a523-280b287c133a">
               <id root="da9e0c23-8a1c-4fbc-8e7e-7bcbef672f32"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular Risk</content>
                  </paragraph>
                  <list listType="unordered" ID="i56513d84-39bd-41fa-8fde-234b431bc953">
                     <item>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see <linkHtml href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0" title="WARNINGS">WARNINGS</linkHtml>).</item>
                     <item>Flurbiprofen is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see <linkHtml href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0" title="WARNINGS">WARNINGS</linkHtml>).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Gastrointestinal Risk</content>
                  </paragraph>
                  <list listType="unordered" ID="i6935d91b-37da-4916-899c-7f64aa37cd72">
                     <item>NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see <linkHtml href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0" title="WARNINGS">WARNINGS</linkHtml>).</item>
                  </list>
               </text>
               <effectiveTime value="20090617"/>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_72e19b7b-cec6-4202-86fe-976c23c88981">
               <id root="9383822f-9236-450a-9a94-03353f710d1b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Flurbiprofen is a member of the phenylalkanoic acid derivative group of non-steroidal anti-inflammatory drugs. Flurbiprofen tablets are beige, round, film-coated tablets for oral administration. Flurbiprofen is a racemic mixture of (+)S- and (-)R-enantiomers. Flurbiprofen, USP is a white or slightly yellow crystalline powder. It is slightly soluble in water at pH 7.0 and readily soluble in most polar solvents. The chemical name is [1,1’-biphenyl]-4-acetic acid, 2-fluoro-alpha-methyl-, (±)-. The molecular weight is 244.26. Its molecular formula is C<sub>15</sub>H<sub>13</sub>FO<sub>2</sub> and it has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="id_9ffadf6b-be99-4208-80f6-e638c33c7f7d">
                     <caption ID="id_4ecf7bb1-6400-4df7-854d-307cd3cf86fd"/>
                  </renderMultiMedia>
                  <paragraph>Each tablet, for oral administration, contains 50 mg or 100 mg flurbiprofen, USP. Inactive ingredients are colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose (anhydrous), magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, titanium dioxide, triacetin, yellow iron oxide and black iron oxide.</paragraph>
               </text>
               <effectiveTime value="20090617"/>
               <component>
                  <observationMedia ID="id_9ffadf6b-be99-4208-80f6-e638c33c7f7d">
                     <text>Structural Formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="0c5d2049-9a48-4721-a893-7ea7e2612e2d-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_40a22834-dae2-460d-a541-9c2fd4a96674">
               <id root="6ab45d05-e279-405a-ab69-ad0ec844e186"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20090617"/>
               <component>
                  <section ID="i4i_pharmacodynamics_id_d5b28a03-28f9-44d8-bfd2-edc22f35d6d7">
                     <id root="411762a0-4bed-7c46-5226-e19a3848b95f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>Pharmacodynamics</title>
                     <text>
                        <paragraph>Flurbiprofen is a non-steroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of flurbiprofen, like that of other non-steroidal anti-inflammatory drugs, is not completely understood but may be related to prostaglandin synthetase inhibition.</paragraph>
                     </text>
                     <effectiveTime value="20061108"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pharmacokinetics_id_f1d9c3f6-e3b9-42ac-97df-3750a58c2aa7">
                     <id root="adb5e80d-ca24-4319-aea6-9fccd1643db2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <effectiveTime value="20090617"/>
                     <component>
                        <section ID="i4i_section_id_0ade332f-e94b-40aa-b584-2caa1a15b032">
                           <id root="b5aeb54c-0796-4adf-ab35-e0285631d558"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Absorption</title>
                           <text>
                              <paragraph>The mean oral bioavailability of flurbiprofen 100 mg tablets is 96% relative to an oral solution. Flurbiprofen is rapidly and non-stereoselectively absorbed with peak plasma concentrations occurring at about 2 hours (see <linkHtml href="#id_dba33001-303b-4091-84a5-9dfedc373c75">Table 1</linkHtml>). Administration of flurbiprofen with either food or antacids may alter the rate but not the extent of flurbiprofen absorption. Ranitidine has been shown to have no effect on either the rate or extent of flurbiprofen absorption.</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_f1bcde67-e024-4f0d-b4d3-b40a1e778dc4">
                           <id root="64262726-f5ad-4884-9db2-7af12d1b4c6c"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Distribution</title>
                           <text>
                              <paragraph>The apparent volume of distribution (Vz/F) of both R- and S-flurbiprofen is approximately 0.12 L/Kg. Both flurbiprofen enantiomers are more than 99% bound to plasma proteins, primarily albumin. Plasma protein binding is relatively constant for the typical average steady-state concentrations (≤ 10 mcg/mL) achieved with recommended doses. Flurbiprofen is poorly excreted into human milk. The nursing infant dose is predicted to be approximately 0.1 mg/day in the established milk of a woman taking flurbiprofen 200 mg/day (see <linkHtml href="#i4i_nursing_mothers_id_d25e34ea-0ec7-49b8-b901-14b5904e634e">PRECAUTIONS: Nursing Mothers</linkHtml>).</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_ab6a50f5-b244-4b91-adce-a8b995c1230d">
                           <id root="f77b4610-f740-b225-d4e6-7ee10250d8a9"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Metabolism</title>
                           <text>
                              <paragraph>Several flurbiprofen metabolites have been identified in human plasma and urine. These metabolites include 4'-hydroxy-flurbiprofen, 3', 4'-dihydroxy-flurbiprofen, 3'-hydroxy-4'-methoxy-flurbiprofen, their conjugates, and conjugated flurbiprofen. Unlike other arylpropionic acid derivatives (e.g., ibuprofen), metabolism of R-flurbiprofen to S-flurbiprofen is minimal. <content styleCode="italics">In vitro</content> studies have demonstrated that cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4'-hydroxy-flurbiprofen. The 4'-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation. Flurbiprofen does not induce enzymes that alter its metabolism.</paragraph>
                              <paragraph>The total plasma clearance of unbound flurbiprofen is not stereoselective, and clearance of flurbiprofen is independent of dose when used within the therapeutic range.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_375c8858-90ca-4ce6-b0f9-2a3690427c46">
                           <id root="496227c4-b768-49ba-a447-bc6a7e624633"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Excretion</title>
                           <text>
                              <paragraph>Following dosing with flurbiprofen, less than 3% of flurbiprofen is excreted unchanged in the urine, with about 70% of the dose eliminated in the urine as parent drug and metabolites. Because renal elimination is a significant pathway of elimination of flurbiprofen metabolites, dosing adjustment in patients with moderate or severe renal dysfunction may be necessary to avoid accumulation of flurbiprofen metabolites. The mean terminal disposition half-lives (t<sub>1/2</sub>) of R- and S-flurbiprofen are similar, about 4.7 and 5.7 hours, respectively. There is little accumulation of flurbiprofen following multiple doses of flurbiprofen.</paragraph>
                              <table width="0.000" ID="id_dba33001-303b-4091-84a5-9dfedc373c75">
                                 <caption ID="id_2b998b41-4cf2-4da4-9ba5-89893a15ce68">Table 1. Mean (SD) R, S-Flurbiprofen Pharmacokinetic Parameters Normalized to a 100 mg Dose of Flurbiprofen</caption>
                                 <col/>
                                 <col/>
                                 <col/>
                                 <col/>
                                 <col/>
                                 <tbody>
                                    <tr ID="id_801c36b8-2ec7-443b-90f1-a2fba0e5b267">
                                       <td align="center" valign="top" styleCode="Botrule Toprule Rrule Lrule">
                                          <paragraph>Pharmacokinetic</paragraph>Parameter</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <paragraph>Normal Healthy</paragraph>
                                          <paragraph>Adults
                                          </paragraph>
                                          <paragraph>(18 to 40 years)</paragraph>N = 15</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <paragraph>Geriatric</paragraph>
                                          <paragraph>Arthritis Patients
                                          </paragraph>
                                          <paragraph>(65 to 83 years)</paragraph>N = 13</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <paragraph>End Stage Renal</paragraph>
                                          <paragraph>Disease Patients<sup>*</sup>
                                          </paragraph>
                                          <paragraph>(23 to 42 years)</paragraph>N = 8</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">
                                          <paragraph>Alcoholic</paragraph>
                                          <paragraph>Cirrhosis Patients
                                          </paragraph>
                                          <paragraph>(31 to 61 years)</paragraph>N = 8</td>
                                    </tr>
                                    <tr ID="id_d24bedca-4fab-4179-88c8-adef6d80b4a5">
                                       <td align="center" valign="top" styleCode="Lrule Botrule Rrule">
                                          <paragraph>Peak</paragraph>
                                          <paragraph>Concentration</paragraph>(Tg/mL)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">14 (4)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">16 (5)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">9
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">9<sup>§</sup>
                                       </td>
                                    </tr>
                                    <tr ID="id_4a0be2cf-0602-4b52-a92a-1588198c12ae">
                                       <td align="center" valign="top" styleCode="Lrule Botrule Rrule">
                                          <paragraph>Time of Peak</paragraph>
                                          <paragraph>Concentration</paragraph>(h)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.9 (1.5)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.2 (3)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.3<sup>§</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1.2<sup>§</sup>
                                       </td>
                                    </tr>
                                    <tr ID="id_fe76c82c-73f0-46d7-843d-c49897720059">
                                       <td align="center" valign="top" styleCode="Lrule Botrule Rrule">
                                          <paragraph>Urinary Recovery</paragraph>
                                          <paragraph>of Unchanged</paragraph>
                                          <paragraph>Flurbiprofen</paragraph>(% of Dose)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.9 (1.3)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0.6 (0.6)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">0.02 (0.02)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">NA
                                       </td>
                                    </tr>
                                    <tr ID="id_e37bddfd-f8e9-4693-bf7a-88c524ec4b21">
                                       <td align="center" valign="top" styleCode="Lrule Botrule Rrule">
                                          <paragraph>Area Under the</paragraph>
                                          <paragraph>Curve (AUC)
                                          </paragraph>(Tg h/mL)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">83 (20)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">77 (24)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">44<sup>§</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">50<sup>§</sup>
                                       </td>
                                    </tr>
                                    <tr ID="id_51e7ad82-9705-4dae-8355-2630842f826e">
                                       <td align="center" valign="top" styleCode="Lrule Botrule Rrule">
                                          <paragraph>Apparent Volume</paragraph>
                                          <paragraph>of Distribution</paragraph>(Vz/F, L)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">14 (3)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">12 (5)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">10<sup>§</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">14<sup>§</sup>
                                       </td>
                                    </tr>
                                    <tr ID="id_7316666c-5cde-4dd6-a128-abcc0852bcc1">
                                       <td align="center" valign="top" styleCode="Lrule Botrule Rrule">
                                          <paragraph>Terminal</paragraph>
                                          <paragraph>Disposition</paragraph>Half-life (t<sub>1/2</sub>, h)</td>
                                       <td align="center" valign="top" styleCode="Rrule">7.5 (0.8)</td>
                                       <td align="center" valign="top" styleCode="Rrule">5.8 (1.9)</td>
                                       <td align="center" valign="top" styleCode="Rrule">3.3
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5.4<sup>Þ</sup>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_6b7c7a8e-d7c0-4da1-b4db-d94df5f70c90">
                     <id root="ab9eb723-770c-4831-b0a6-f8bf2205153a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Special Populations</title>
                     <effectiveTime value="20090617"/>
                     <component>
                        <section ID="i4i_section_id_e272c3b0-9fd9-476d-afc1-8d00dc92a28b">
                           <id root="fca06c7a-6e87-543d-b1a3-1475bfccc93b"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Pediatric</title>
                           <text>
                              <paragraph>The pharmacokinetics of flurbiprofen have not been investigated in pediatric patients.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_df832be4-1727-4a63-b1ef-dc2e9ebef21e">
                           <id root="c9b8a07a-0d61-4cc8-ff5d-1b43c8edacf3"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Race</title>
                           <text>
                              <paragraph>No pharmacokinetic differences due to race have been identified.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_2c1e2d4b-a917-40fb-9077-520db6390039">
                           <id root="856d0e5e-6a9b-250b-5204-61cc7b696444"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Geriatric</title>
                           <text>
                              <paragraph>Flurbiprofen pharmacokinetics were similar in geriatric arthritis patients, younger arthritis patients, and young healthy volunteers receiving flurbiprofen tablets 100 mg as either single or multiple doses.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_a9f515fc-00a2-44fe-bcfc-8022691e9e15">
                           <id root="fef09bc0-6c63-4e04-b674-a3a065792b47"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Hepatic Insufficiency</title>
                           <text>
                              <paragraph>Hepatic metabolism may account for &gt; 90% of flurbiprofen elimination, so patients with hepatic disease may require reduced doses of flurbiprofen tablets compared to patients with normal hepatic function. The pharmacokinetics of R- and S-flurbiprofen were similar, however, in alcoholic cirrhosis patients (N = 8) and young healthy volunteers (N = 8) following administration of a single 200 mg dose of flurbiprofen tablets. </paragraph>
                              <paragraph>Flurbiprofen plasma protein binding may be decreased in patients with liver disease and serum albumin concentrations below 3.1 g/dL (see <content styleCode="italics">
                                    <linkHtml href="#i4i_section_id_a662a4fa-cf6e-46d6-aeda-8d1f5ce60673">PRECAUTIONS: General: Hepatic Effects</linkHtml>
                                 </content>).</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_6b08cd5a-0d9e-4bb6-a0b8-20807d7dea67">
                           <id root="9bedbbcb-2b7d-428a-b554-a572f15f01b9"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Renal Insufficiency</title>
                           <text>
                              <paragraph>Renal clearance is an important route of elimination for flurbiprofen metabolites, but a minor route of elimination for unchanged flurbiprofen (≤ 3% of total clearance). The unbound clearances of R- and S-flurbiprofen did not differ significantly between normal healthy volunteers (N = 6, 50 mg single dose) and patients with renal impairment (N = 8, inulin clearances ranging from 11 to 43 mL/min, 50 mg multiple doses). Flurbiprofen plasma protein binding may be decreased in patients with renal impairment and serum albumin concentrations below 3.9 g/dL. Elimination of flurbiprofen metabolites may be reduced in patients with renal impairment (see <content styleCode="italics">
                                    <linkHtml href="#i4i_precautions_general_id_562c82d9-349b-433a-b09a-c166605fd305">PRECAUTIONS: General: Renal Effects</linkHtml>
                                 </content>).</paragraph>
                              <paragraph>Flurbiprofen is not significantly removed from the blood into dialysate in patients undergoing continuous ambulatory peritoneal dialysis.</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_e9f205ed-34bd-457b-a579-b97a67cf1c71">
                     <id root="841a50ff-73bf-4274-919d-afb0fe944087"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Drug-Drug Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">(see also <content styleCode="bold">
                                 <linkHtml href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</linkHtml>
                              </content>)</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20090617"/>
                     <component>
                        <section ID="i4i_section_id_cc58c2a3-722e-443b-8a87-753dacae5101">
                           <id root="c6be4cb5-ff9e-63e0-b0f2-fa1e0135016f"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Antacids</title>
                           <text>
                              <paragraph>Administration of flurbiprofen to volunteers under fasting conditions or with antacid suspension yielded similar serum flurbiprofen-time profiles in young adult subjects (n = 12). In geriatric subjects (n = 7), there was a reduction in the rate but not the extent of flurbiprofen absorption.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_6f23b519-0936-4a96-968c-082f44e3b600">
                           <id root="458de05c-28d4-47ba-8891-bc1e19695bfd"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Aspirin</title>
                           <text>
                              <paragraph>Concurrent administration of flurbiprofen and aspirin resulted in 50% lower serum flurbiprofen concentrations. This effect of aspirin (which is also seen with other non-steroidal anti-inflammatory drugs) has been demonstrated in patients with rheumatoid arthritis (n = 15) and in healthy volunteers (n = 16) (see <linkHtml href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</linkHtml>).</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_cabd5909-b700-4b79-b1bf-8f37d6636e99">
                           <id root="62efd001-462d-42f4-9d9f-babf470f897b"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Beta-Adrenergic Blocking Agents</title>
                           <text>
                              <paragraph>The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10). Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol. Flurbiprofen did not appear to affect the beta-blocker-mediated reduction in heart rate. Flurbiprofen did not affect the pharmacokinetic profile of either drug (see <linkHtml href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</linkHtml>).</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_03db3f5f-61eb-4d6c-8a8d-2f5bca464b00">
                           <id root="b8f0aa98-507c-5e24-bc27-6ab741106c73"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Cimetidine, Ranitidine</title>
                           <text>
                              <paragraph>In normal volunteers (n = 9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics, except for a small (13%) but statistically significant increase in the area under the serum concentration curve of flurbiprofen in subjects who received cimetidine.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_83381a6b-b711-49b2-990b-b4f0ff17251e">
                           <id root="9b34fe8d-40bf-a9ba-7a9f-7053532d2afa"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Digoxin</title>
                           <text>
                              <paragraph>In studies of healthy males (n = 14), concomitant administration of flurbiprofen and digoxin did not change the steady-state serum levels of either drug.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_d1018c9c-adc1-49a7-94eb-212a6e0e86e7">
                           <id root="01c798ab-e5ee-489e-b71f-e48f0c59bf7b"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Diuretics</title>
                           <text>
                              <paragraph>Studies in healthy volunteers have shown that, like other non-steroidal anti-inflammatory drugs, flurbiprofen can interfere with the effects of furosemide. Although results have varied from study to study, effects have been shown on furosemide-stimulated diuresis, natriuresis, and kaliuresis. Other non-steroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide and potassium-sparing diuretics (see <linkHtml href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</linkHtml>).</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_0ddefbb6-bad0-4216-8c80-414f6f20fce4">
                           <id root="c9bd2977-1ea6-4aee-bbb4-f76e4690513b"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Lithium</title>
                           <text>
                              <paragraph>In a study of 11 women with bipolar disorder receiving lithium carbonate at a dosage of 600 mg to 1200 mg/day, administration of 100 mg flurbiprofen every 12 hours increased plasma lithium concentrations by 19%. Four of 11 patients experienced a clinically important increase (&gt; 25% or &gt; 0.2 mmol/L). Non-steroidal anti-inflammatory drugs have also been reported to decrease the renal clearance of lithium by about 20% (see <linkHtml href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</linkHtml>).</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_bead1324-11d7-4d35-bd0d-650b6b1d6b8c">
                           <id root="84b0ec87-5fd4-a0bd-fa8f-a6b39c9bc6db"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Methotrexate</title>
                           <text>
                              <paragraph>In a study of six adult arthritis patients, coadministration of methotrexate (10 to 25 mg/dose) and flurbiprofen (300 mg/day) resulted in no observable interaction between these two drugs.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_65b03665-35f4-4558-a54b-86726b91fa2d">
                           <id root="ed02994c-d514-fb28-b4f3-97726e2daf15"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Oral Hypoglycemic Agents</title>
                           <text>
                              <paragraph>In a clinical study, flurbiprofen was administered to adult diabetics who were already receiving glyburide (n = 4), metformin (n = 2), chlorpropamide with phenformin (n = 3), or glyburide with phenformin (n = 6). Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_c8adda3d-3c3a-4807-bf45-fc5fe766dae4">
               <id root="82256321-a295-4cd9-ac20-d3b2cee87f7b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of flurbiprofen tablets and other treatment options before deciding to use flurbiprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <linkHtml href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0" title="WARNINGS">WARNINGS</linkHtml>).</paragraph>
                  <paragraph>Flurbiprofen tablets are indicated:</paragraph>
                  <list listType="unordered" ID="i00832bbf-1167-47bd-8181-930cdb336b9a">
                     <item>For relief of the signs and symptoms of rheumatoid arthritis.</item>
                     <item>For relief of the signs and symptoms of osteoarthritis.</item>
                  </list>
               </text>
               <effectiveTime value="20090617"/>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_e118260c-6d3a-403f-9e90-11277c717f2a">
               <id root="b24b91f5-5905-40fd-8615-d582aa88bf03"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Flurbiprofen tablets are contraindicated in patients with known hypersensitivity to flurbiprofen tablets or the excipients (see <linkHtml href="#i4i_description_id_72e19b7b-cec6-4202-86fe-976c23c88981" title="DESCRIPTION">DESCRIPTION</linkHtml>).</paragraph>
                  <paragraph> Flurbiprofen should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs. Severe, rarely fatal, anaphylactic-like reactions to non-steroidal anti-inflammatory drugs have been reported in such patients (see <linkHtml href="#i4i_section_id_6d9e24e5-eeb5-46fb-b5e5-020f2889a65f">WARNINGS: Anaphylactoid Reactions</linkHtml> and <content styleCode="italics">
                        <linkHtml href="#i4i_section_id_6828baed-f416-4913-8a3d-0ae8f70881b3">PRECAUTIONS: General: Preexisting Asthma</linkHtml>
                     </content>). </paragraph>
                  <paragraph> Flurbiprofen is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see <linkHtml href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0" title="WARNINGS">WARNINGS</linkHtml>).</paragraph>
               </text>
               <effectiveTime value="20090617"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0">
               <id root="76237f9d-cb05-468a-9a7e-101fa79b3a5a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34071-1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <effectiveTime value="20090617"/>
               <component>
                  <section ID="i4i_section_id_14d2419f-441b-4445-9319-6af08c4535f2">
                     <id root="ef02dbdd-2a0a-4b83-9f2f-ec77187ba37a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Cardiovascular Effects</title>
                     <effectiveTime value="20090617"/>
                     <component>
                        <section ID="i4i_section_id_d53f9a44-40b1-458d-804f-ef3d55100296">
                           <id root="e75310e5-6831-44c8-a029-85151cf7c044"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Cardiovascular Thrombotic Events</title>
                           <text>
                              <paragraph>Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.</paragraph>
                              <paragraph> There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see <linkHtml href="#i4i_section_id_710dcb11-5e4f-4514-a453-c1d2b17d9b46">WARNINGS: Gastrointestinal Effects</linkHtml>).</paragraph>
                              <paragraph> Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke (see <linkHtml href="#i4i_contraindications_id_e118260c-6d3a-403f-9e90-11277c717f2a" title="CONTRAINDICATIONS">CONTRAINDICATIONS</linkHtml>).</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_80fee509-268b-4b94-9fd1-152c56cf643f">
                           <id root="eb96f324-0ea8-0a0f-d978-1eec750fa66c"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Hypertension</title>
                           <text>
                              <paragraph>NSAIDs, including flurbiprofen, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including flurbiprofen, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_200fb1d7-cda4-4bf5-a54d-0ed88712547d">
                           <id root="074a585f-043f-4171-a1cb-07f049ad9e85"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Congestive Heart Failure and Edema</title>
                           <text>
                              <paragraph>Fluid retention and edema have been observed in some patients taking NSAIDs. Flurbiprofen should be used with caution in patients with fluid retention or heart failure.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_710dcb11-5e4f-4514-a453-c1d2b17d9b46">
                     <id root="5d9d5766-10ff-4f7e-9124-52bf349f3245"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Gastrointestinal Effects</title>
                     <effectiveTime value="20090617"/>
                     <component>
                        <section ID="i4i_section_id_890d0f40-1001-4b17-ac47-978eb3264f23">
                           <id root="9d669ba7-786b-42cf-ac85-ddee18bba29b"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Risk of Ulceration, Bleeding, and Perforation</title>
                           <text>
                              <paragraph>NSAIDs, including flurbiprofen, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.</paragraph>
                              <paragraph> NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Patients with a <content styleCode="italics">prior history of peptic ulcer disease and/or gastrointestinal bleeding </content>who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients treated with neither of these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population. </paragraph>
                              <paragraph> To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulcerations and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. </paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_50d6c226-dbeb-4ca6-aa4e-27ee7c5cbe6c">
                     <id root="88665ff5-aad3-473c-9f4b-8c3aefde3c0c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Renal Effects</title>
                     <text>
                        <paragraph>Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</paragraph>
                     </text>
                     <effectiveTime value="20090617"/>
                     <component>
                        <section ID="i4i_section_id_52cc338d-9c6f-4ec9-a8fa-9289a09440b7">
                           <id root="24eebbca-4895-4af2-a68d-aa37a9b989c7"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Advanced Renal Disease</title>
                           <text>
                              <paragraph>In clinical studies, the elimination half-life of flurbiprofen was unchanged in patients with renal impairment. Flurbiprofen metabolites are eliminated primarily by the kidneys. Elimination of 4'-hydroxy-flurbiprofen was reduced in patients with moderate to severe renal impairment. Therefore, treatment with flurbiprofen is not recommended in these patients with advanced renal disease. If flurbiprofen therapy must be initiated, close monitoring of the patients renal function is advisable (see <linkHtml href="#i4i_clinical_pharmacology_id_40a22834-dae2-460d-a541-9c2fd4a96674" title="CLINICAL PHARMACOLOGY">CLINICAL PHARMACOLOGY</linkHtml>).</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_6d9e24e5-eeb5-46fb-b5e5-020f2889a65f">
                     <id root="844573c5-0a47-46d6-a01e-1adbfe7da37d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Anaphylactoid Reactions</title>
                     <text>
                        <paragraph>As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to flurbiprofen. Flurbiprofen should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see <linkHtml href="#i4i_contraindications_id_e118260c-6d3a-403f-9e90-11277c717f2a" title="CONTRAINDICATIONS">CONTRAINDICATIONS</linkHtml> and <content styleCode="italics">
                              <linkHtml href="#i4i_section_id_6828baed-f416-4913-8a3d-0ae8f70881b3">PRECAUTIONS: General: Preexisting Asthma</linkHtml>
                           </content>). Emergency help should be sought in cases where an anaphylactoid reaction occurs.</paragraph>
                     </text>
                     <effectiveTime value="20090617"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_4c3b0a24-f38a-4bba-8b7b-a19d8f3ece14">
                     <id root="4a672613-394a-30d1-2b28-5c300da484da"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>In late pregnancy, as with other NSAIDs, flurbiprofen should be avoided because it may cause premature closure of the ductus arteriosus.</paragraph>
                     </text>
                     <effectiveTime value="20061108"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_precautions_id_03effa84-5701-4d42-8589-68e2cb55a195">
               <id root="4138258d-3de7-4d9b-9e03-d5b788522ed8"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42232-9" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20090617"/>
               <component>
                  <section ID="i4i_precautions_general_id_562c82d9-349b-433a-b09a-c166605fd305">
                     <id root="4d3b5626-593f-4dea-abea-4676309c404e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34072-9" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Flurbiprofen cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.</paragraph>
                        <paragraph> The pharmacological activity of flurbiprofen in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.</paragraph>
                     </text>
                     <effectiveTime value="20090617"/>
                     <component>
                        <section ID="i4i_section_id_a662a4fa-cf6e-46d6-aeda-8d1f5ce60673">
                           <id root="fb4db197-862c-4a58-9040-76f788c1eb9b"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Hepatic Effects</title>
                           <text>
                              <paragraph>Borderline elevations of one or more liver tests may occur in up to 15% of patients taking non-steroidal anti-inflammatory drugs, including flurbiprofen. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with non-steroidal anti-inflammatory drugs. In addition, rare cases of severe hepatic reactions, including jaundice, fulminant hepatitis, liver necrosis, and hepatic failure, some of them with fatal outcomes have been reported.</paragraph>
                              <paragraph> A patient with symptoms and/or signs suggesting liver dysfunction, or with abnormal liver test values, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with flurbiprofen. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), flurbiprofen should be discontinued. </paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_234c0ec3-dffe-4d5c-927b-d36d90234bd8">
                           <id root="e836d3ae-ce1a-4300-83d9-ccde773ccbe1"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Hematological Effects</title>
                           <text>
                              <paragraph>Anemia is sometimes seen in patients receiving non-steroidal anti-inflammatory drugs, including flurbiprofen. This may be due to fluid retention, GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with non-steroidal anti-inflammatory drugs, including flurbiprofen, should have their hemoglobin or hematocrit checked periodically even if they do not exhibit any signs or symptoms of anemia.</paragraph>
                              <paragraph> Non-steroidal anti-inflammatory drugs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Flurbiprofen does not generally affect platelet counts, prothrombin time (PT), or partial thromboplastin time (PTT). Patients receiving flurbiprofen who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_6828baed-f416-4913-8a3d-0ae8f70881b3">
                           <id root="53847546-1d44-6d93-f70b-59ce04af62a2"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Preexisting Asthma</title>
                           <text>
                              <paragraph>Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal. Since cross-reactivity, including bronchospasm, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, flurbiprofen should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_2893f495-fa42-47c2-ac01-fb5a7c853a9e">
                           <id root="3724727e-7dfa-4710-46f1-cc17a5fa3bbe"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Vision Changes</title>
                           <text>
                              <paragraph>Blurred and/or diminished vision has been reported with the use of flurbiprofen and other non-steroidal anti-inflammatory drugs. Patients experiencing eye complaints should have ophthalmologic examinations.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_info_patients_id_485e5d57-b265-43cf-aa88-bf508407a6f2">
                     <id root="280930e4-4132-40b4-8bc7-7e1083142315"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.</paragraph>
                        <list listType="unordered" ID="i2635e5c0-1eca-4a90-8638-67c71b3211e7">
                           <item>Flurbiprofen, like other NSAIDs, may cause CV side effects, such as MI or stroke, which may result in hospitalization and even death. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up (see <linkHtml href="#i4i_section_id_14d2419f-441b-4445-9319-6af08c4535f2">WARNINGS: Cardiovascular Effects</linkHtml>).</item>
                           <item>Flurbiprofen, like other NSAIDs, can cause GI discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, which may result in hospitalization and even death. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms including epigastric pain, dyspepsia, melena, and hematemesis. Patients should be apprised of the importance of this follow-up (see <content styleCode="italics">
                                 <linkHtml href="#i4i_section_id_890d0f40-1001-4b17-ac47-978eb3264f23">WARNINGS: Gastrointestinal Effects: Risk of Ulceration, Bleeding, and Perforation</linkHtml>
                              </content>).</item>
                           <item>Flurbiprofen, like other NSAIDs, can cause serious skin side effects such as exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and even death. Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever, or other signs of hypersensitivity such as itching, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of rash and contact their physicians as soon as possible. </item>
                           <item>Patients should promptly report signs or symptoms of unexplained weight gain or edema to their physicians.</item>
                           <item>Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness and “flu-like” symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.</item>
                           <item>Patients should be informed of the signs of an anaphylactoid reaction (e.g. difficulty breathing, swelling of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see <linkHtml href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0" title="WARNINGS">WARNINGS</linkHtml>).</item>
                           <item>In late pregnancy, as with other NSAIDs, flurbiprofen should be avoided because it may cause premature closure of the ductus arteriosus.</item>
                        </list>
                     </text>
                     <effectiveTime value="20090617"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_lab_tests_id_0aaf18b5-6ae7-4c5c-b9db-86dc6f67ff1b">
                     <id root="87a1a378-dc6c-4f56-afce-df1a7f08a5db"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34075-2" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph>Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with non-steroidal anti-inflammatory drugs should have their CBC and chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash, etc.) or abnormal liver tests persist or worsen, flurbiprofen should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20061108"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">
                     <id root="14e06068-7a37-4f11-ae3e-6ba6101446d9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <effectiveTime value="20090617"/>
                     <component>
                        <section ID="i4i_section_id_26222964-2e1a-4fb1-9cd1-7e1b7f4c04f1">
                           <id root="7ec007e8-2f92-24c9-d7d4-84e8104248db"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>ACE Inhibitors</title>
                           <text>
                              <paragraph>Reports suggest that non-steroidal anti-inflammatory drugs may diminish the antihypertensive effect of ACE inhibitors. These interactions should be given consideration in patients taking non-steroidal anti-inflammatory drugs concomitantly with ACE inhibitors.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_9f3865ba-a564-426f-874b-d6cae17b0618">
                           <id root="d0fcf2a0-a904-18c8-3865-abe0400ede65"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Anticoagulants</title>
                           <text>
                              <paragraph>The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone. The physician should be cautious when administering flurbiprofen to patients taking warfarin or other anticoagulants.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_859ea3cd-91da-4e07-910c-4bc86fc4a396">
                           <id root="d767f03a-bd0c-4531-b356-be5c20f96d35"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Aspirin</title>
                           <text>
                              <paragraph>Concurrent administration of aspirin lowers serum flurbiprofen concentrations (see <linkHtml href="#i4i_section_id_e9f205ed-34bd-457b-a579-b97a67cf1c71">CLINICAL PHARMACOLOGY: Drug-Drug Interactions</linkHtml>). The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of flurbiprofen and aspirin is not generally recommended because of the potential for increased adverse effects.</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_7ee6a48f-a1f2-46ca-b631-8392da035df1">
                           <id root="ee60d5db-0b4e-4487-a4e2-f798b394f849"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Beta-Adrenergic Blocking Agents</title>
                           <text>
                              <paragraph>Flurbiprofen attenuated the hypotensive effect of propranolol but not atenolol (see <linkHtml href="#i4i_section_id_e9f205ed-34bd-457b-a579-b97a67cf1c71">CLINICAL PHARMACOLOGY: Drug-Drug Interactions</linkHtml>). The mechanism underlying this interference is unknown. Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_5d53c591-30c3-4a27-9162-e5b65c4cc76d">
                           <id root="b5a10e9c-6878-4a0c-b00d-a663db99f0cf"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Diuretics</title>
                           <text>
                              <paragraph>Clinical studies, as well as post-marketing observations, have shown that flurbiprofen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see <linkHtml href="#i4i_section_id_50d6c226-dbeb-4ca6-aa4e-27ee7c5cbe6c">WARNINGS: Renal Effects</linkHtml>), as well as diuretic efficacy.</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_c7c177cb-fae4-493b-b7e3-0582e4dabdf5">
                           <id root="827ad781-524b-43c3-a8c7-583467489635"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Lithium</title>
                           <text>
                              <paragraph>NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. </paragraph>
                              <paragraph> These effects have been attributed to inhibition of renal prostaglandin synthesis by the non-steroidal anti-inflammatory drugs. Thus, when non-steroidal anti-inflammatory drugs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_section_id_80add559-71d4-48e3-b910-f507ececdc39">
                           <id root="c7af45f9-5add-e988-5a65-4ea90b916359"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Methotrexate</title>
                           <text>
                              <paragraph>Non-steroidal anti-inflammatory drugs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when non-steroidal anti-inflammatory drugs are administered concomitantly with methotrexate.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pregnancy_id_97959db7-c474-4897-9d34-77b7182e07e1">
                     <id root="40d24df5-e141-4138-a1d4-90ff32758b59"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20090617"/>
                     <component>
                        <section ID="i4i_teratogenic_id_b552ccf3-37b4-4191-a824-f0037bad8849">
                           <id root="8316700a-1925-4bad-9646-21e72b268a51"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="34077-8" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>Teratogenic Effects. Pregnancy Category C</title>
                           <text>
                              <paragraph>Reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities. However, animal reproduction studies are not always predictive of human response. There are no adequate and well controlled studies in pregnant women. <content styleCode="underline">Flurbiprofen should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus</content>.</paragraph>
                           </text>
                           <effectiveTime value="20090617"/>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_non_teratogenic_id_b34580d5-3f9e-4a31-b8e1-99528b6c61f7">
                           <id root="f49f5cbf-0507-4afa-8481-d3e571410644"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="34078-6" displayName="NONTERATOGENIC EFFECTS SECTION"/>
                           <title>Nonteratogenic Effects</title>
                           <text>
                              <paragraph>Because of the known effects of non-steroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during late pregnancy should be avoided.</paragraph>
                           </text>
                           <effectiveTime value="20061108"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_labour_delivery_id_9557eaea-535e-4246-b498-cc0702d6b69f">
                     <id root="2af12879-8c01-98e1-03eb-a5cd5ec82e66"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34079-4" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>Labor and Delivery</title>
                     <text>
                        <paragraph>In rat studies with non-steroidal anti-inflammatory drugs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of flurbiprofen on labor and delivery in pregnant women are unknown.</paragraph>
                     </text>
                     <effectiveTime value="20061108"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_d25e34ea-0ec7-49b8-b901-14b5904e634e">
                     <id root="904f1214-b170-2359-ce04-fa7c3ab452ae"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34080-2" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Concentrations of flurbiprofen in breast milk and plasma of nursing mothers suggest that a nursing infant could receive approximately 0.10 mg flurbiprofen per day in the established milk of a woman taking flurbiprofen 200 mg/day. Because of possible adverse effects of prostaglandin-inhibiting drugs on neonates, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20061108"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_ffd27473-f7d2-49a3-819f-7e68f3d3a8a1">
                     <id root="1ad170ab-ba60-8c6d-61bc-af552d2ce695"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20061108"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_6f211012-fd93-4279-9f19-82a3a9e30708">
                     <id root="2d9b55dc-5cbb-40e1-8f18-8bdd2d78f0ba"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>As with any NSAID, caution should be exercised in treating the elderly (65 years and older). Clinical experience with flurbiprofen suggests that elderly patients may have a higher incidence of gastrointestinal complaints than younger patients, including ulceration, bleeding, flatulence, bloating, and abdominal pain. To minimize the potential risk for gastrointestinal events, the lowest effective dose should be used for the shortest possible duration (see <linkHtml href="#i4i_section_id_710dcb11-5e4f-4514-a453-c1d2b17d9b46">WARNINGS: Gastrointestinal Effects</linkHtml>). Likewise, elderly patients are at greater risk of developing renal decompensation (see <linkHtml href="#i4i_section_id_50d6c226-dbeb-4ca6-aa4e-27ee7c5cbe6c">WARNINGS: Renal Effects</linkHtml>). </paragraph>
                        <paragraph> The pharmacokinetics of flurbiprofen do not seem to differ in elderly patients from those in younger individuals (see <linkHtml href="#i4i_section_id_6b7c7a8e-d7c0-4da1-b4db-d94df5f70c90">CLINICAL PHARMACOLOGY: Special Populations</linkHtml>). The rate of absorption of flurbiprofen was reduced in elderly patients who also received antacids, although the extent of absorption was not affected (see <linkHtml href="#i4i_section_id_e9f205ed-34bd-457b-a579-b97a67cf1c71">CLINICAL PHARMACOLOGY: Drug-Drug Interactions</linkHtml>).</paragraph>
                     </text>
                     <effectiveTime value="20090617"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_62a168e3-f072-4819-a2a6-3b1f6bff67f9">
               <id root="75a8bbfc-c5a0-4942-a726-b21e8073277b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <table width="0.000" ID="id_496913c3-5a71-4e15-a3e5-d99518d6f363">
                     <caption ID="id_8931abab-d855-4d19-aa6d-858c77b4f873">TABLE 2. Reported adverse events in patients receiving flurbiprofen or other non-steroidal anti-inflammatory drugs</caption>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr ID="id_4f783294-945a-4077-8784-a94e07b17816">
                           <td align="center" valign="top" colspan="3" styleCode="Botrule Toprule Rrule Lrule">Reported in patients treated with flurbiprofen</td>
                           <td align="center" valign="top" rowspan="2" styleCode="Botrule Rrule">
                              <paragraph>Reported in patients</paragraph>
                              <paragraph>treated with other</paragraph>
                              <paragraph>products but not</paragraph>flurbiprofen</td>
                        </tr>
                        <tr ID="id_4ef0a30f-e4d2-4a75-a587-97ad563b9a1b">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>Incidence of 1%</paragraph>or greater 
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>Incidence &lt; 1% -</paragraph>
                              <paragraph>Causal Relationship</paragraph>Probable
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>Incidence &lt; 1% -</paragraph>
                              <paragraph>Causal Relationship</paragraph>Unknown <sup>†</sup>
                           </td>
                        </tr>
                        <tr ID="id_8a76e6c9-4918-4e37-a559-66baf9b810ed">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>BODY AS A WHOLE</paragraph>     edema</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>anaphylactic</paragraph>
                              <paragraph>      reaction</paragraph>
                              <paragraph>chills</paragraph>fever</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule"/>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>&lt; 1%:</paragraph>
                              <paragraph>death</paragraph>
                              <paragraph>infection</paragraph>sepsis</td>
                        </tr>
                        <tr ID="id_e3e3dee5-d4e9-4c84-b7b9-65038ab5be57">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>CARDIOVASCULAR</paragraph> SYSTEM</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>congestive heart</paragraph>
                              <paragraph>      failure</paragraph>
                              <paragraph>hypertension</paragraph>
                              <paragraph>vascular diseases</paragraph>vasodilation</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>angina pectoris</paragraph>
                              <paragraph>arrhythmias</paragraph>myocardial infarction</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>&lt; 1%:</paragraph>
                              <paragraph>hypotension</paragraph>
                              <paragraph>palpitations</paragraph>
                              <paragraph>syncope</paragraph>
                              <paragraph>tachycardia</paragraph>vasculitis</td>
                        </tr>
                        <tr ID="id_621b268c-3a9f-4a10-aaa9-28a88286daf0">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>DIGESTIVE SYSTEM</paragraph>
                              <paragraph>    abdominal pain</paragraph>
                              <paragraph>     constipation</paragraph>
                              <paragraph>     diarrhea</paragraph>
                              <paragraph>      dyspepsia/heartburn</paragraph>
                              <paragraph>     elevated liver enzymes</paragraph>
                              <paragraph>     flatulence</paragraph>
                              <paragraph>     GI bleeding</paragraph>
                              <paragraph>     nausea</paragraph>     vomiting</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>bloody diarrhea</paragraph>
                              <paragraph>esophageal disease</paragraph>
                              <paragraph>gastric/peptic ulcer</paragraph>
                              <paragraph>      disease</paragraph>
                              <paragraph>gastritis</paragraph>
                              <paragraph>jaundice</paragraph>
                              <paragraph>      (cholestatic and</paragraph>
                              <paragraph>      noncholestatic)</paragraph>
                              <paragraph>hematemesis</paragraph>
                              <paragraph>hepatitis</paragraph>stomatitis/glossitis</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>appetite changes</paragraph>
                              <paragraph>cholecystitis</paragraph>
                              <paragraph>colitis</paragraph>
                              <paragraph>dry mouth</paragraph>
                              <paragraph>exacerbation of</paragraph>
                              <paragraph>      inflammatory</paragraph>
                              <paragraph>      bowel disease</paragraph>
                              <paragraph>periodontal abscess</paragraph>
                              <paragraph>small intestine</paragraph>
                              <paragraph>      inflammation with</paragraph>
                              <paragraph>      loss of blood and</paragraph>      protein</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>&gt; 1%:</paragraph>
                              <paragraph>GI perforation</paragraph>
                              <paragraph>GI ulcers</paragraph>
                              <paragraph>      (gastric/duodenal)</paragraph>
                              <paragraph>
                                 <br/>&lt; 1%:</paragraph>
                              <paragraph>eructation</paragraph>
                              <paragraph>liver failure</paragraph>
                              <paragraph>pancreatitis</paragraph>
                           </td>
                        </tr>
                        <tr ID="id_a87dab34-27ac-4d5a-b676-6522617164bf">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>HEMIC AND LYMPHATIC</paragraph>SYSTEM</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>aplastic anemia</paragraph>
                              <paragraph>      (including</paragraph>
                              <paragraph>      agranulocytosis</paragraph>
                              <paragraph>      or pancytopenia)</paragraph>
                              <paragraph>decrease in</paragraph>
                              <paragraph>      hemoglobin and</paragraph>
                              <paragraph>      hematocrit</paragraph>
                              <paragraph> ecchymosis/purpura</paragraph>
                              <paragraph>eosinophilia</paragraph>
                              <paragraph>hemolytic anemia</paragraph>
                              <paragraph>iron deficiency</paragraph>
                              <paragraph>      anemia</paragraph>
                              <paragraph>leucopenia</paragraph>thrombocytopenia</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>lymphadenopathy</paragraph>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>&gt; 1%:</paragraph>
                              <paragraph>anemia</paragraph>
                              <paragraph>increased bleeding</paragraph>
                              <paragraph>      time</paragraph>
                              <paragraph>
                                 <br/>&lt; 1%:</paragraph>
                              <paragraph>melena</paragraph>rectal bleeding</td>
                        </tr>
                        <tr ID="id_ee58b177-e0d6-4d01-9d08-c9493a271e02">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>METABOLIC AND</paragraph>
                              <paragraph>NUTRITIONAL SYSTEM</paragraph>     body weight changes</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <br/>
                              <br/>hyperuricemia</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <br/>
                              <br/>hyperkalemia</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <br/>
                              <br/>
                              <paragraph>&lt; 1%:</paragraph>hyperglycemia</td>
                        </tr>
                        <tr ID="id_5be6a07e-8568-4d01-b189-7fc0063ef376">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>NERVOUS SYSTEM</paragraph>
                              <paragraph>     headache</paragraph>
                              <paragraph>     nervousness and other</paragraph>
                              <paragraph>           manifestations of</paragraph>
                              <paragraph>            central nervous</paragraph>
                              <paragraph>            system (CNS)</paragraph>
                              <paragraph>            stimulation (e.g.,</paragraph>
                              <paragraph>           anxiety, insomnia,</paragraph>
                              <paragraph>           increased reflexes,</paragraph>
                              <paragraph>      tremor)</paragraph>
                              <paragraph>      symptoms associated</paragraph>
                              <paragraph>            with CNS inhibition</paragraph>
                              <paragraph>           (e.g., amnesia, asthenia,</paragraph>
                              <paragraph>            depression, malaise,</paragraph>           somnolence)</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>ataxia</paragraph>
                              <paragraph>cerebrovascular</paragraph>
                              <paragraph> ischemia</paragraph>
                              <paragraph>confusion</paragraph>
                              <paragraph>paresthesia</paragraph>twitching</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>convulsion</paragraph>
                              <paragraph>cerebrovascular</paragraph>
                              <paragraph>      accident</paragraph>
                              <paragraph>emotional lability</paragraph>
                              <paragraph>hypertonia</paragraph>
                              <paragraph>meningitis</paragraph>
                              <paragraph>myasthenia</paragraph>
                              <paragraph>subarachnoid</paragraph>     hemorrhage</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>&lt; 1%:</paragraph>
                              <paragraph>coma</paragraph>
                              <paragraph>dream abnormalities</paragraph>
                              <paragraph>drowsiness</paragraph>hallucinations</td>
                        </tr>
                        <tr ID="id_0469b945-b91a-41c3-99ef-a7d731cec5aa">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>RESPIRATORY SYSTEM</paragraph>      rhinitis</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>asthma</paragraph>epistaxis</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>bronchitis </paragraph>
                              <paragraph>dyspnea</paragraph>
                              <paragraph>hyperventilation</paragraph>
                              <paragraph>laryngitis</paragraph>
                              <paragraph>pulmonary embolism</paragraph>pulmonary infarct</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>&lt; 1%:</paragraph>
                              <paragraph>pneumonia</paragraph>
                              <paragraph>respiratory</paragraph>      depression</td>
                        </tr>
                        <tr ID="id_1c948f3f-80b5-45c3-b286-c27ff21d926c">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>SKIN AND APPENDAGES</paragraph>     Rash</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>angioedema</paragraph>
                              <paragraph>eczema</paragraph>
                              <paragraph>exfoliative</paragraph>
                              <paragraph>      dermatitis</paragraph>
                              <paragraph>photosensitivity</paragraph>
                              <paragraph>pruritus</paragraph>
                              <paragraph>toxic epidermal</paragraph>
                              <paragraph>      necrolysis</paragraph>urticaria</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>alopecia</paragraph>
                              <paragraph>dry skin</paragraph>
                              <paragraph>herpes simplex/zoster</paragraph>
                              <paragraph>nail disorder</paragraph>sweating</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>&lt; 1%:</paragraph>
                              <paragraph>erythema</paragraph>
                              <paragraph>      multiforme</paragraph>
                              <paragraph>Stevens Johnson</paragraph>      Syndrome</td>
                        </tr>
                        <tr ID="id_41443be7-e044-4108-994a-ca510b104979">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>SPECIAL SENSES</paragraph>
                              <paragraph>      changes in vision</paragraph>
                              <paragraph>      dizziness/vertigo</paragraph>      tinnitus</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>conjunctivitis</paragraph>parosmia</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>changes in taste</paragraph>
                              <paragraph>corneal opacity</paragraph>
                              <paragraph>ear disease</paragraph>
                              <paragraph>glaucoma</paragraph>
                              <paragraph>retinal hemorrhage</paragraph>
                              <paragraph>retrobulbar neuritis</paragraph>transient hearing loss</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>&gt; 1%:</paragraph>
                              <paragraph>pruritus</paragraph>
                              <paragraph>
                                 <br/>&lt; 1%:</paragraph>hearing impairment</td>
                        </tr>
                        <tr ID="id_d0dded6f-9fe3-4461-a801-493ba86110e4">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">
                              <paragraph>UROGENITAL SYSTEM</paragraph>
                              <paragraph>     signs and symptoms</paragraph>
                              <paragraph>          suggesting urinary</paragraph>          tract infection</td>
                           <td align="left" valign="top" styleCode="Rrule">
                              <paragraph>
                                 <br/>hematuria</paragraph>
                              <paragraph>interstitial nephritis</paragraph>renal failure</td>
                           <td align="left" valign="top" styleCode="Rrule">
                              <paragraph>
                                 <br/>menstrual</paragraph>
                              <paragraph>     disturbances</paragraph>
                              <paragraph>prostate disease</paragraph>
                              <paragraph>vaginal and uterine</paragraph>
                              <paragraph>      hemorrhage</paragraph>vulvovaginitis</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <br/>&gt; 1%:</paragraph>
                              <paragraph>abnormal renal</paragraph>
                              <paragraph> function</paragraph>
                              <paragraph>
                                 <br/>&lt; 1%:</paragraph>
                              <paragraph>dysuria</paragraph>
                              <paragraph>oliguria</paragraph>
                              <paragraph>polyuria</paragraph>proteinuria</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20090617"/>
            </section>
         </component>
         <component>
            <section ID="i4i_overdosage_id_15eef4c4-8768-490c-93ad-df4ead2332fe">
               <id root="54e1b5f8-2a5d-9119-d584-55113d30c7ce"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Symptoms following acute overdoses with non-steroidal anti-inflammatory drugs are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of non-steroidal anti-inflammatory drugs, and may occur following an overdose.</paragraph>
                  <paragraph>Patients should be managed by symptomatic and supportive care following overdose with a non-steroidal anti-inflammatory drug. There are no specific antidotes. Emesis and/or activated charcoal (60 g to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms, or following a large overdose (5 to 10 times the usual dose). Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.</paragraph>
               </text>
               <effectiveTime value="20061108"/>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_a3e21215-ba42-4114-a26a-1d4d393c38ca">
               <id root="b3d3554f-7e58-4c04-a07f-7b43a79f72ca"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of flurbiprofen and other treatment options before deciding to use flurbiprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <linkHtml href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0" title="WARNINGS">WARNINGS</linkHtml>).</paragraph>
                  <paragraph> After observing the response to initial therapy with flurbiprofen, the dose and frequency should be adjusted to suit an individual patient’s needs.</paragraph>
                  <paragraph>For relief of the signs and symptoms of rheumatoid arthritis or osteoarthritis, the recommended starting dose of flurbiprofen is 200 mg to 300 mg per day, divided for administration two, three, or four times a day. The largest recommended single dose in a multiple-dose daily regimen is 100 mg.</paragraph>
               </text>
               <effectiveTime value="20090617"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_67d00beb-d47f-4313-becc-e503610b9947">
               <id root="c7a79dba-48a6-44bc-bbae-d902167c50cb"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Flurbiprofen tablets, USP are available containing 100 mg of flurbiprofen, USP.</paragraph>
                  <br/>
                  <paragraph>The 100 mg tablets are film-coated beige, round, unscored, tablets debossed with <content styleCode="bold">M</content> over <content styleCode="bold">93 </content>on one side of the tablet and blank on the other side. They are available as follows:</paragraph>
                  <table width="30%" ID="i8c53fc03-9002-49b6-8e28-295878ffcb67">
                     <tbody>
                        <tr>
                           <td>Bottles of 20<br/>
                           </td>
                           <td>NDC 54868-3362-0<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 60<br/>
                           </td>
                           <td>NDC 54868-3362-1<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Bottles of 100<br/>
                           </td>
                           <td>NDC 54868-3362-2<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from light.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</paragraph>
                  <paragraph>
                     <content styleCode="bold">PHARMACIST:</content> Dispense a Medication Guide with each prescription.</paragraph>
                  <paragraph>Mylan Pharmaceuticals Inc.<br/>Morgantown, WV 26505</paragraph>
                  <paragraph>REVISED JUNE 2009<br/>FRB:R9mc</paragraph>
                  <br/>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Relabeling and Repackaging by:</content>
                     <br/>Physicians Total Care, Inc.<br/>Tulsa, Oklahoma       74146<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20120612"/>
            </section>
         </component>
         <component>
            <section ID="i4i_medguide_id_e12cb92c-095e-47a5-a1b2-42109bfaf844">
               <id root="5365c86e-f46e-4b33-af90-36dc69a7216d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42231-1" displayName="SPL MEDGUIDE SECTION"/>
               <title>Medication Guide <br/>for <br/>Non-Steroidal Anti-Inflammatory Drugs <br/>(NSAIDs)</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines may increase the chance of a heart attack or stroke that can lead to death.</content> This chance increases: </paragraph>
                  <list listType="unordered" ID="i5215a1c9-6d45-4fd8-8a1b-3a7511b1e7fe">
                     <item>with longer use of NSAID medicines </item>
                     <item>in people who have heart disease </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines should never be used right before or after a heart surgery called a “coronary artery bypass graft (CABG).”</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines can cause ulcers and bleeding in the stomach and intestines at any time during treatment. Ulcers and bleeding: </content>
                  </paragraph>
                  <list listType="unordered" ID="ia1f0caf5-9689-4f0f-87b7-4939c8ac83c3">
                     <item>can happen without warning symptoms </item>
                     <item>may cause death <list listType="unordered" ID="i1dfed230-131e-4567-8c8b-f2304c2b6c4c">
                           <item>
                              <caption> </caption>
                              <content styleCode="bold">The chance of a person getting an ulcer or bleeding increases with: </content>
                              <list listType="unordered" ID="ie9e2b685-ddb1-4ee8-881f-22d0d5fa6a14">
                                 <item>taking medicines called “corticosteroids” and “anticoagulants” </item>
                                 <item>longer use </item>
                                 <item>smoking </item>
                                 <item>drinking alcohol </item>
                                 <item>older age </item>
                                 <item>having poor health </item>
                              </list>
                           </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines should only be used: </content>
                  </paragraph>
                  <list listType="unordered" ID="i1807dae0-3483-41c2-86c1-150a9d61ab5a">
                     <item>exactly as prescribed </item>
                     <item>at the lowest dose possible for your treatment </item>
                     <item>for the shortest time needed </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </content>
                  </paragraph>
                  <paragraph>NSAID medicines are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as: </paragraph>
                  <list listType="unordered" ID="i12532be5-e597-493a-8099-5e61b611b641">
                     <item>different types of arthritis </item>
                     <item>menstrual cramps and other types of short-term pain</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take an NSAID medicine: </content>
                  </paragraph>
                  <list listType="unordered" ID="i306297b7-d95b-4e25-8ed7-4e50e4ab2abf">
                     <item>if you had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAID medicine </item>
                     <item>for pain right before or after heart bypass surgery</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider: </content>
                  </paragraph>
                  <list listType="unordered" ID="i20d4d311-7ed7-4455-8a1f-9d89f28c557a">
                     <item>about all of your medical conditions.</item>
                     <item>about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. <content styleCode="bold">Keep a list of your medicines to show to your healthcare provider and pharmacist. </content>
                     </item>
                     <item>if you are pregnant. <content styleCode="bold">NSAID medicines should not be used by pregnant women late in their pregnancy.</content>
                     </item>
                     <item>if you are breastfeeding. <content styleCode="bold">Talk to your doctor.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </content>
                  </paragraph>
                  <table width="0.000" ID="id_22f1595d-023a-4d02-b98f-6103cb7d616d">
                     <col/>
                     <col/>
                     <tbody>
                        <tr ID="id_46eb0324-da8c-4049-aae6-0a9ad224705b">
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Serious side effects include:</content>
                              </paragraph>
                              <list listType="unordered" ID="i4053717b-53b1-42fc-8e91-6b05d5ce92a2">
                                 <item>heart attack</item>
                                 <item>stroke</item>
                                 <item>high blood pressure</item>
                                 <item>heart failure from body swelling (fluid retention)</item>
                                 <item>kidney problems including kidney failure</item>
                                 <item>bleeding and ulcers in the stomach and intestine</item>
                                 <item>low red blood cells (anemia)</item>
                                 <item>life-threatening skin reactions</item>
                                 <item>life-threatening allergic reactions</item>
                                 <item>liver problems including liver failure</item>
                                 <item>asthma attacks in people who have asthma</item>
                              </list>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule">
                              <paragraph>
                                 <content styleCode="bold">Other side effects include:</content>
                              </paragraph>
                              <list listType="unordered" ID="id6594a30-0192-4f0b-82fc-8c3ff59d7ff9">
                                 <item>stomach pain</item>
                                 <item>constipation</item>
                                 <item>diarrhea</item>
                                 <item>gas</item>
                                 <item>heart burn</item>
                                 <item>nausea</item>
                                 <item>vomiting</item>
                                 <item>dizziness</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Get emergency help right away if you have any of the following symptoms: </content>
                  </paragraph>
                  <list listType="unordered" ID="i74ef2ec7-71a9-47a0-8a23-296aee51ff11">
                     <item>shortness of breath or trouble breathing </item>
                     <item>chest pain </item>
                     <item>weakness  in one part or side of your body </item>
                     <item>slurred speech </item>
                     <item>swelling of the face or throat </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms: </content>
                  </paragraph>
                  <list listType="unordered" ID="i65d8f3a7-c667-4e60-8620-aebe7bfb08c3">
                     <item>nausea </item>
                     <item>more tired or weaker than usual </item>
                     <item>itching </item>
                     <item>your skin or eyes look yellow </item>
                     <item>stomach pain </item>
                     <item>flu-like symptoms </item>
                     <item>vomit blood </item>
                     <item>there is blood in your bowel movement or it is black and sticky like tar </item>
                     <item>unusual weight gain </item>
                     <item>skin rash or blisters with fever </item>
                     <item>swelling of the arms and legs, hands and feet </item>
                  </list>
                  <paragraph>These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) </content>
                  </paragraph>
                  <list listType="unordered" ID="i24ecc361-62b0-430e-8f50-08a39d3e4f4f">
                     <item>Aspirin is an NSAID medicine but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines. </item>
                     <item>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</item>
                  </list>
                  <table width="0.000" ID="id_e2c18ed5-ec4c-4030-ba2c-ec5bda14f959">
                     <caption ID="id_fe8b196b-a8b6-4e7a-b9cd-883907af7d93">NSAID medicines that need a prescription</caption>
                     <col/>
                     <col/>
                     <tbody>
                        <tr ID="id_bdde43e8-1ccf-4c16-bbd8-0d891ac62a77">
                           <td align="left" valign="top" styleCode="Botrule Toprule Rrule Lrule">
                              <content styleCode="bold">Generic Name</content>
                           </td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">
                              <content styleCode="bold">Tradename</content>
                           </td>
                        </tr>
                        <tr ID="id_cddb69ac-3bc4-4aea-b803-7ba3c6a54de5">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Celecoxib</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Celebrex</td>
                        </tr>
                        <tr ID="id_52990b99-1314-4217-8384-989e1cdd3604">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Diclofenac</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Cataflam, Voltaren, Arthrotec (combined with misoprostol)</td>
                        </tr>
                        <tr ID="id_1ebe66a7-5f11-4de3-9a36-da561311a7c6">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Diflunisal</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Dolobid</td>
                        </tr>
                        <tr ID="id_37934a42-e37c-415a-b7f1-ce1146cd041e">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Etodolac</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Lodine, Lodine XL</td>
                        </tr>
                        <tr ID="id_9af00b00-8c62-41ef-91e5-a59ce560ab6f">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Fenoprofen</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Nalfon, Nalfon 200</td>
                        </tr>
                        <tr ID="id_1a108e7d-3bab-46d0-a973-9b8484620d11">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Flurbiprofen</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Ansaid</td>
                        </tr>
                        <tr ID="id_472586be-15ff-4274-8cc1-9ae6a05324e4">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Ibuprofen</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Motrin, Tab-Profen, Vicoprofen (combined with hydrocodone), Combunox (combined with oxycodone)</td>
                        </tr>
                        <tr ID="id_139638c6-f60f-431a-8296-1a91883b98f6">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Indomethacin</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Indocin, Indocin SR, Indo-Lemmon, Indomethagan</td>
                        </tr>
                        <tr ID="id_cacda1ba-fa9f-42c3-a35e-01fa11761516">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Ketoprofen</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Oruvail</td>
                        </tr>
                        <tr ID="id_6eb1e096-54f4-4b5c-86cb-4d7303362a5a">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Ketorolac</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Toradol</td>
                        </tr>
                        <tr ID="id_37e8051e-5ae2-4ca3-9263-4fa742276b23">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Mefenamic Acid</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Ponstel</td>
                        </tr>
                        <tr ID="id_3751c890-960a-417b-a13b-df0249f9b676">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Meloxicam</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Mobic</td>
                        </tr>
                        <tr ID="id_c11a7a88-e2b1-4708-a564-4287b8343777">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Nabumetone</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Relafen</td>
                        </tr>
                        <tr ID="id_b85fc19a-c46d-40b7-8594-25acb746488c">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Naproxen</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Naprosyn, Anaprox, Anaprox DS, EC-Naproxyn, Naprelan, Naprapac (copackaged with lansoprazole)</td>
                        </tr>
                        <tr ID="id_aad43457-8b6c-4787-b44b-d9ce0708289d">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Oxaprozin</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Daypro</td>
                        </tr>
                        <tr ID="id_b3d2bd36-9aca-48f5-8b2b-a5ba784542c1">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Piroxicam</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Feldene</td>
                        </tr>
                        <tr ID="id_0c37f108-1f94-45dd-9e59-a10f58278f19">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Sulindac</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Clinoril</td>
                        </tr>
                        <tr ID="id_ccee5af4-1469-4950-a1d0-2b48639c9d55">
                           <td align="left" valign="top" styleCode="Lrule Botrule Rrule">Tolmetin</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Tolectin, Tolectin DS, Tolectin 600</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="italics">This Medication Guide has been approved by the U.S. Food and Drug Administration.</content>
                  </paragraph>
                  <paragraph>Revised 06/2009</paragraph>
               </text>
               <effectiveTime value="20090617"/>
            </section>
         </component>
         <component>
            <section ID="i4i_Principal_display_panel_id_7bcb7b8c-dc76-4693-a4b5-153b45f11b1e">
               <id root="a7200fd3-2946-4e69-950d-2a1e86b88f9f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 100 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ATTENTION:</content>
                     <br/>
                     <content styleCode="bold">Dispense with</content>
                     <br/>
                     <content styleCode="bold">Medication Guide</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FLURBIPROFEN<br/>TABLETS, USP<br/>100 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(Rx only)</content>
                  </paragraph>
                  <paragraph>Each tablet contains:<br/>Flurbiprofen, USP <content styleCode="bold">. . . . </content>100 mg</paragraph>
                  <paragraph>Dispense in a tight, light-resistant<br/>container as defined in the USP<br/>using a child-resistant closure.</paragraph>
                  <paragraph>Keep container tightly closed.</paragraph>
                  <paragraph>Keep this and all medication<br/>out of the reach of children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20° to 25°C (68° to 77°F).<br/>[See USP for Controlled Room<br/>Temperature.]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from light.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Usual Dosage:</content> See accompanying<br/>prescribing information.</paragraph>
                  <renderMultiMedia referencedObject="id_75401380-da29-4790-8b9d-fc1da84b9671"/>
               </text>
               <effectiveTime value="20120612"/>
               <component>
                  <observationMedia ID="id_75401380-da29-4790-8b9d-fc1da84b9671">
                     <text>Flurbiprofen Tablets 100 mg Bottles</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3362.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>